In terms of cytokine secretion and activation, cladribine only increased IL-6 production at the 2 μM concentration (Figure 3c, Supplemental Table S9) and decreased production of TNF-α at 0.2 μM (Figure 3d, Supplemental Table S10), which are far from the maximum concentration of the drug that reaches the CNS in MS patients, in addition this effect was not consistent across experiments (see Figure 3h, Supplemental Table S14). This evidence concerns the gene IL6 and myeloid sarcoma.